Drug Profile
GSK 1292263
Alternative Names: GSK1292263Latest Information Update: 10 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antihyperglycaemics; Antihyperlipidaemics; Small molecules
- Mechanism of Action GPR119 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hyperlipidaemia; Type 2 diabetes mellitus
Most Recent Events
- 11 Aug 2011 GlaxoSmithKline completes a phase II trial in Hyperlipidaemia (in combination with atorvastatin) in US (NCT01218204)
- 23 Sep 2010 Phase-II clinical trials in Hyperlipidaemia in USA (PO)
- 01 Mar 2010 GlaxoSmithKline completes a phase I trial in Healthy volunteers in USA